In REDEFINE 4, CagriSema achieved 23.0% weight loss at 84 weeks under the efficacy estimand, compared to 25.5% with tirzepatide. Clinically, how meaningful is a 23% reduction in body weight over 84 weeks in patients with a baseline mean weight of 114.2 kg?

The trial did not meet its primary endpoint of non-inferiority versus tirzepatide 15 mg. From a clinical and statistical standpoint, how significant is this outcome, particularly in an open-label head-to-head design?

When applying the treatment-regimen estimand, weight loss was 20.2% with CagriSema versus 23.6% with tirzepatide. How should clinicians interpret the gap between the efficacy estimand and the treatment-regimen estimand results?

REDEFINE 4 was conducted as an open-label study, meaning both investigators and participants were aware of treatment allocation. How might this design influence adherence, discontinuation rates, or patient expectations compared to a double-blind trial?

CagriSema combines semaglutide (GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analogue). Mechanistically, how does amylin biology potentially add to GLP-1–mediated weight loss, and what advantages might this combination offer long term?

CagriSema demonstrated a safety profile consistent with the GLP-1 class, with predominantly mild-to-moderate gastrointestinal adverse events. In the context of chronic obesity treatment, how important is tolerability relative to incremental differences in efficacy?

Novo Nordisk plans to initiate a higher-dose Phase 3 trial (2.4 mg/7.2 mg). Based on the REDEFINE 4 data, what would you expect in terms of efficacy gains versus potential tolerability trade-offs?

CagriSema has already been submitted to the FDA based on REDEFINE 1 and 2, with a decision anticipated by late 2026. How do the REDEFINE 4 results influence its competitive positioning against tirzepatide and other emerging obesity therapies?